SIRT2 Recombinant Antibody
Applications
Reactivity
| Overview | |
| Catalog # | bsm-52221r-20uL |
| Product Name | SIRT2 Recombinant Antibody |
| Applications |
WB
IHC-P
IHC-F
IF(IHC-P)
|
| Reactivity | Human, Mouse, Rat |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | Recombinant human SIRT2 protein, around C-terminal 150aa. |
| Clonality | Recombinant |
| Isotype | IgG |
| Concentration | Lot dependent |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| Storage Condition | Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target | |
| Gene ID | 22933 |
| Swiss Prot | Q8IXJ6 |
| Subcellular location | Cytoplasm |
| Synonyms | NAD-dependent protein deacetylase sirtuin-2; SIRT2 |
| Background | NAD-dependent protein deacetylase, which deacetylates internal lysines on histone and alpha-tubulin as well as many other proteins such as key transcription factors. Participates in the modulation of multiple and diverse biological processes such as cell cycle control, genomic integrity, microtubule dynamics, cell differentiation, metabolic networks, and autophagy. Plays a major role in the control of cell cycle progression and genomic stability. Functions in the antephase checkpoint preventing precocious mitotic entry in response to microtubule stress agents, and hence allowing proper inheritance of chromosomes. Positively regulates the anaphase promoting complex/cyclosome (APC/C) ubiquitin ligase complex activity by deacetylating CDC20 and FZR1, then allowing progression through mitosis. Associates both with chromatin at transcriptional start sites (TSSs) and enhancers of active genes. Plays a role in cell cycle and chromatin compaction through epigenetic modulation of the regulation of histone H4 'Lys-20' methylation (H4K20me1) during early mitosis. Specifically deacetylates histone H4 at 'Lys-16' (H4K16ac) between the G2/M transition and metaphase enabling H4K20me1 deposition by KMT5A leading to ulterior levels of H4K20me2 and H4K20me3 deposition throughout cell cycle, and mitotic S-phase progression. Deacetylates KMT5A modulating KMT5A chromatin localization during the mitotic stress response. |
| Application Dilution | |
| WB | 1:500-2000 |
| IHC-P | IHC-P1:100-500 |
| IHC-F | IHC-F1:100-500 |
| IF(IHC-P) | IFIHC-P1:100-500 |
Frequently asked questions
Which applications is SIRT2 Recombinant Antibody (bsm-52221R) validated for, and at what dilution?
bsm-52221R is validated for WB(WB) (1:500-2000); IHC-P(IHC-P) (1:100-500); IHC-F(IHC-F) (1:100-500); IF(IHC-P)(IF(IHC-P)) (1:100-500). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does SIRT2 Recombinant Antibody (bsm-52221R) react with?
Tested reactivity: Human, Mouse, Rat.
How should bsm-52221R be stored?
Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. Storage buffer: 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol
What immunogen was used to raise SIRT2 Recombinant Antibody (bsm-52221R)?
Recombinant human SIRT2 protein, around C-terminal 150aa.